[ Kezar Life Sciences raises $50M in Series B funding ]

Kezar Life Sciences has raised $50 million in Series B funding.

Founded in 2015, Kezar Life Sciences is a company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders.

The new financing will help propel the autoimmune disease candidate into the next stage of testing.

Funding Series B
Founded  2015
Country  USA
City  South San Francisco, California
Founder / CEO  John Fowler
Deal Size  $50M
Investors  Cowen Group
 Aju IB Investment
 Omega Funds
 EcoR1 Capital
 Bay City Capital
 Morningside Group
 Pappas Ventures
 Cormorant Asset Management
 Qiming Venture Partners
Previous Investors  Morningside Group
 Cormorant Asset Management
 EcoR1 Capital
 9W Capital Management
 Omega Funds
 Aju IB Investment